By William Langbein
NEW YORK (Reuters Health) – A retrospective analysis of a 300-patient trial of ReoPro (abciximab) indicates that the drug improves the survival of diabetics undergoing angioplasty after acute myocardial infarction.
Investigators from University Hospital, Pitie-Salpetriere in Paris presented the findings at the scientific sessions of the American Heart Association in Anaheim, California. The data were extracted from the ADMIRAL trial, a randomized, double-blind, placebo-controlled phase III study that compared ReoPro with placebo in coronary stenting of MI patients. Professor Gilles Montalescot of University Hospital directed the ADMIRAL trial.
Based on a prespecified 6-month analysis of patients with diabetes in the ADMIRAL trial, the investigators determined that ReoPro-treated diabetics were less likely than controls to die during the 6 months following the procedure. None of the ReoPro-treated diabetics died, compared with a 16.7% mortality rate in the placebo group.
ReoPro-treated diabetics also appeared to fare better when the researchers evaluated the combined endpoint of death, MI recurrence and initiation of urgent revascularization procedures. Only 20.7% of ReoPro-treated diabetics experienced such events compared with half of the placebo group.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!